Olanzapine and risperidone disrupt conditioned avoidance responding in phencyclidine-pretreated or amphetamine- Pretreated rats by selectively weakening motivational salience of conditioned stimulus

Behavioural Pharmacology

Volumn 20, Issue 1, 2009, Pages 84-98

  Li, Ming ^a   He, Wei ^a   Mead, Alexa ^a  

^a UNIVERSITY OF NEBRASKA LINCOLN   (United States)

Author keywords

Amphetamine sensitization; Conditioned avoidance response; Motivational salience; Olanzapine; Phencyclidine sensitization; Rat risperidone

Indexed keywords

AMPHETAMINE; OLANZAPINE; PHENCYCLIDINE; RISPERIDONE; BENZODIAZEPINE DERIVATIVE; DEXAMPHETAMINE; NEUROLEPTIC AGENT;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; AVOIDANCE BEHAVIOR; BEHAVIOR; CONDITIONING; CONTROLLED STUDY; DRUG EFFECT; DRUG MECHANISM; EXPERIMENTAL MODEL; LOCOMOTION; MALE; MOTIVATION; NONHUMAN; RAT; SCHIZOPHRENIA; SENSITIZATION; ANIMAL; ANIMAL BEHAVIOR; CHEMICALLY INDUCED DISORDER; DISEASE MODEL; DRUG INTERACTION; MOTOR ACTIVITY; PSYCHOLOGY; SPRAGUE DAWLEY RAT;

ANIMALS; ANTIPSYCHOTIC AGENTS; AVOIDANCE LEARNING; BEHAVIOR, ANIMAL; BENZODIAZEPINES; CONDITIONING (PSYCHOLOGY); DEXTROAMPHETAMINE; DISEASE MODELS, ANIMAL; DRUG INTERACTIONS; MOTIVATION; MOTOR ACTIVITY; PHENCYCLIDINE; RATS; RATS, SPRAGUE-DAWLEY; RISPERIDONE; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY;

EID: 61449196749     PISSN: 09558810     EISSN: None     Source Type: Journal    
DOI: 10.1097/FBP.0b013e3283243008     Document Type: Article

References (61)

1. Ader R, Clink DW (1957). Effects of chlorpromazine on the acquisition and extinction of an avoidance response in the rat. J Pharmacol Exp Ther 131:144-148.
2. Arnt J (1982). Pharmacological specificity of conditioned avoidance response inhibition in rats: inhibition by neuroleptics and correlation to dopamine receptor blockade. Acta Pharmacol Toxicol (Copenh) 51:321-329.
3. Barrett JE (2002). The emergence of behavioral pharmacology. Mol Intervent 2:470-475.
4. Barrett JE, Bergman J Peter B (2008). Dews and pharmacological studies on behavior. J Pharmacol Exp Ther 326:683-690.
5. Bell DS (1965). Comparison of amphetamine psychosis and schizophrenia. Br J Psychiatry 111:701 -707.
6. Beninger RJ (1989). The role of serotonin and dopamine in learning to avoid aversive stimuli. In: Archer T, Nilsson L, editors. Aversion, avoidance, and anxiety: perspective on aversively motivated behavior. Hillsdale, New Jersey: Lawrence Erlbaum Associates, pp. 265-284.
7. Berridge KC, Robinson TE (1998). What is the role of dopamine in reward: hedonic impact, reward learning, or incentive salience? Brain Res Brain Res Rev 28:309-369.
8. Bignami G (1978). Effects of neuroleptics, ethanol, hypnotic-sedatives, tranquilizers, narcotics, and minor stimulants in aversive paradigma In: Anisman H, Bignami G, editors. Psychopharmacology of aversively motivated behavior. New York and London: Plenum Press, pp. 385-453.
9. Bruto V, Beauchamp C, Zacharko RM, Anisman H (1984). Amphetamine-induced perseverative behavior in a radial arm maze following DSP4 or 6-OHDA pretreatment. Psychopharmacology (Berl) 83:62-69.
10. Castner SA, Vosler PS, Goldman-Rakic PS (2005). Amphetamine sensitization impairs cognition and reduces dopamine turnover in primate prefrontal cortex. Biol Psychiatry 57:743-751.
11. Cook L, Davidson AB (1978.) Behavioral pharmacology: animal models invovling aversive control of behavior. In: Lipton MA, DiMascio A Killam K, editors. Psychopharmacology. a generation of progress. New York: Raven, pp. 563-567.
12. Dews PB (1976). Interactions of behavioral effects of drugs. Ann N Y Acad Sci 281:50-63.
13. Dunn MJ, Killcross S (2006). Clozapine but not haloperidol treatment reverses sub-chronic phencyclidine-induced disruption of conditional discrimination performance. Behav Brain Res 175:271-277.
14. Ellenbroek BA, Cools AR (2000). Animal models for the negative symptoms of schizophrenia. Behav Pharmacol 11:223-233.
15. Featherstone RE, Kapur S, Fletcher PJ (2007). The amphetamine-induced sensitized state as a model of schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry 31:1556-1571.
16. Fletcher PJ, Tenn CC, Rizos Z, Lovic V, Kapur S (2005). Sensitization to amphetamine, but not PCP, impairs attentional set shifting: reversal by a D1 receptor agonist injected into the medial prefrontal cortex Psychopharmacology (Berl) 183: 190-200.
17. Geyer MA, Krebs-Thomson K, Braff DL, Swerdlow NR (2001). Pharmacological studies of prepulse inhibition models of sensorimotor gating deficits in schizophrenia: a decade in review. Psychopharmacology (Berl) 156:117-154.
18. Itil T, Keskiner A, Kiremitci N, Holden JM (1967). Effect of phencyclidine in chronic schizophrenics. Can Psychiatr Assoc J 12:209-212.
19. Janowsky DS, Risch C (1979). Amphetamine psychosis and psychotic symptoms. Psychopharmacology (Berl) 65:73-77.
20. Janssen PAJ, Niemegeers CJE, Schellekens KHL (1965). Is it possible to predict the clinical effects of neuroleptic drugs (major tranquilizers) from animal data? Arzneimittelforschung 15:104-117.
21. Javitt DC, Zukin SR (1991). Recent advances in the phencyclidine model of schizophrenia. Am J Psychiatry 148:1301-1308.
22. Jentsch JD, Anzivino LA (2004). A low dose of the alpha2 agonist clonidine ameliorates the visual attention and spatial working memory deficits produced by phencyclidine administration to rats. Psychopharmacology (Berl) 175:76-83.
23. Jentsch JD, Roth RH (1999). The neuropsychopharmacology of phencyclidine: from NMDA receptor hypofunction to the dopamine hypothesis of schizophrenia. Neuropsychopharmacology 20:201 -225.
24. Jentsch JD, Taylor JR (2001). Impaired inhibition of conditioned responses produced by subchronic administration of phencyclidine to rats. Neuropsychopharmacology 24:66-74.
25. Jentsch JD, Tran A, Le D, Youngren KD, Roth RH (1997). Subchronic phencyclidine administration reduces mesoprefrontal dopamine utilization and impairs prefrontal cortical-dependent cognition in the rat. Neuropsychopharmacology 17:92-99.
26. Kapur S (2003). Psychosis as a state of aberrant salience: a framework linking biology, phenomenology, and pharmacology in schizophrenia. Am J Psychiatry 160:13-23.
27. Kapur S, Remington G (2001). Atypical antipsychotics: new directions and new challenges in the treatment of schizophrenia. Annu Rev Med 52:503-517.
28. Kapur S, VanderSpek SC, Brownlee BA, Nobrega JN (2003). Antipsychotic dosing in preclinical models is often unrepresentative of the clinical condition: a suggested solution based on in vivo occupancy. J Pharmacol Exp Ther 305:625-631.
29. Kuribara H, Tadokoro S (1981). Correlation between antiavoidance activities of antipsychotic drugs in rats and daily clinical doses. Pharmacol Biochem Behav 14:181-192.
30. M, Parkes J, Fletcher PJ, Kapur S (2004). Evaluation of the motor initiation hypothesis of APD-induced conditioned avoidance decreases. Pharmacol Biochem Behav 78:811-819.
31. M, Fletcher PJ, Kapur S (2007). Time course of the antipsychotic effect and the underlying behavioral mechanisms. Neuropsychopharmacology 32:263-272.
32. Marrs W, Kuperman J, Avedian T, Roth RH, Jentsch JD (2005). Alpha-2 adrenoceptor activation inhibits phencyclidine-induced deficits of spatial working memory in rats. Neuropsychopharmacology 30:1500-1510.
33. Martinez V, Parikh V, Sarter M (2005). Sensitized attentional performance and Fos-immunoreactive cholinergic neurons in the basal forebrain of ampheta-mine-pretreated rats. Biol Psychiatry 57:1138-1146.
34. McMillan DE, Katz JL (2002). Continuing implications of the early evidence against the drive-reduction hypothesis of the behavioral effects of drugs. Psychopharmacology (Berl) 163:251-264.
35. Murphy CA, Fend M, Russig H, Feldon J (2001). Latent inhibition, but not prepulse inhibition, is reduced during withdrawal from an escalating dosage
36. schedule of amphetamine. Behav Neurosci 115:1247-1256.
37. Murray JB (2002). Phencyclidine (PCP): a dangerous drug, but useful in schizophrenia research. J Psychol 136:319-327.
38. Nestler EJ (2001). Molecular neurobiology of addiction. Am J Addict 10:201-217.
39. Peleg-Raibstein D, Feldon J (2008). Effects of withdrawal from an escalating dose of amphetamine on conditioned fear and dopamine response in the
40. medial prefrontal cortex. Behav Brain Res 186:12-22.
41. Peleg-Raibstein D, Sydekum E, Feldon J (2006). Differential effects on prepulse inhibition of withdrawal from two different repeated administration schedules of amphetamine. Int J Neuropsychopharmacol 9:737-749.
42. Pezze MA, Feldon J, Murphy CA (2002). Increased conditioned fear response and altered balance of dopamine in the shell and core of the nucleus accumbens during amphetamine withdrawal. Neuropharmacology 42:633-643.
43. Phillips M, Wang C, Johnson KM (2001). Pharmacological characterization of locomotor sensitization induced by chronic phencyclidine administration. J Pharmacol Exp Ther 296:905-913.
44. Robinson TE, Becker JB (1986). Enduring changes in brain and behavior produced by chronic amphetamine administration: a review and evaluation of animal models of amphetamine psychosis. Brain Res 396:157-198.
45. Rodefer JS, Murphy ER, Baxter MG (2005). PDE10A inhibition reverses subchronic PCP-induced deficits in attentional set-shifting in rats. Eur J Neurosci 21:1070-1076.
46. Russig H, Murphy CA, Feldon J (2002). Clozapine and haloperidol reinstate latent inhibition following its disruption during amphetamine withdrawal. Neuropsychopharmacology 26:765-777.
47. Russig H, Murphy CA, Feldon J (2003). Prepulse inhibition during withdrawal from an escalating dosage schedule of amphetamine. Psychopharmacology (Berl) 169:340-353.
48. Sams-Dodd F (1998a). Effects of continuous D-amphetamine and phencyclidine administration on social behaviour, stereotyped behaviour, and locomotor activity in rats. Neuropsychopharmacology 19:18-25.
49. Sams-Dodd F (1998b). A test of the predictive validity of animal models of schizophrenia based on phencyclidine and D-amphetamine. Neuropsychopharmacology 18:293-304.
50. Salamone JD, Correa M (2002). Motivational views of reinforcement: implications for understanding the behavioral functions of nucleus accumbens dopamine. Behav Brain Res 137:3-25.
51. Segal DS, Mandell AJ (1974). Long-term administration of d-amphetamine: progressive augmentation of motor activity and stereotypy. Pharmacol Biochem Behav 2:249-255.
52. Segal DS, Geyer MA, Schuckit MA (1981). Stimulant-induced psychosis: an evaluation of animal methods. Essays Neurochem Neuropharmacol 5:95-129.
53. Shannon HE, Hart JC, Bymaster FP, Calligaro DO, DeLapp NW, Mitch CH, et al. (1999). Muscarinic receptor agonists, like dopamine receptor antagonist antipsychotics, inhibit conditioned avoidance response in rats. J Pharmacol Exp Ther 290:901-907.
54. Snyder SH (1973). Amphetamine psychosis: a 'model' schizophrenia mediated by catecholamines. Am J Psychiatry 130:61-67.
55. Spealman RD, Kelleher RT, Goldberg SR, DeWeese J, Goldberg DM (1983). Behavioral effects of clozapine: comparison with thioridazine, chlorpromazine, haloperidol and chlordiazepoxide in squirrel monkeys. J Pharmacol Exp Ther 224:127-134.
56. Tenn CC, Fletcher PJ, Kapur S (2003). Amphetamine-sensitized animals show a sensorimotor gating and neurochemical abnormality similar to that of schizophrenia. Schizophr Res 64:103-114.
57. Tenn CC, Kapur S, Fletcher PJ (2005). Sensitization to amphetamine, but not phencyclidine, disrupts prepulse inhibition and latent inhibition. Psychopharmacology (Berl) 180:366-376.
58. Van der Heyden JA, Bradford LD (1988). A rapidly acquired one-way conditioned avoidance procedure in rats as a primary screening test for antipsychotics: influence of shock intensity on avoidance performance. Behav Brain Res 31:61-67.
59. Wadenberg ML, Hicks PB (1999). The conditioned avoidance response test re-evaluated: is it a sensitive test for the detection of potentially atypical antipsychotics? Neurosci Biobehav Rev 23:851-862.
60. Wise RA (2004). Dopamine, learning and motivation. Nat Rev Neurosci 5:483-494.
61. Xu X, Domino EF (1994). Phencyclidine-induced behavioral sensitization. Pharmacol Biochem Behav 47:603-608.